Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRSS12 | P56730 | 1/20 | 0.57 |
| ▸ | CHEK2 | O96017 | 8/20 | 0.54 |
| ▸ | MMP2 | P08253 | 2/20 | 0.50 |
| ▸ | MMP9 | P14780 | 2/20 | 0.50 |
| ▸ | MMP8 | P22894 | 2/20 | 0.50 |
| ▸ | MMP13 | P45452 | 2/20 | 0.50 |
| ▸ | COMT | P21964 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.49 |
| ▸ | HPSE | Q9Y251 | 1/20 | 0.48 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11949020 | 0.96 | PRSS12 (0.61) | PRSS12CHEK2COMTMAPTHDAC6 | |
| SCHEMBL11948988 | 0.93 | MMP2 (0.56) | PRSS12CHEK2MMP2MMP9MMP8 | |
| SCHEMBL11949024 | 0.92 | PRSS12 (0.56) | PRSS12CHEK2MMP2MMP9MMP8 | |
| SCHEMBL11956441 | 0.92 | PRSS12 (0.56) | PRSS12CHEK2COMTMAPTHDAC6 | |
| SCHEMBL11949029 | 0.92 | PRSS12 (0.56) | PRSS12CHEK2COMTMAPTHDAC6 | |
| SCHEMBL11949041 | 0.92 | PRSS12 (0.56) | PRSS12CHEK2COMTMAPTHDAC6 | |
| SCHEMBL11949023 | 0.92 | PRSS12 (0.61) | PRSS12CHEK2COMTHDAC6 | |
| SCHEMBL11949022 | 0.91 | PRSS12 (0.58) | PRSS12CHEK2MMP2MMP9MMP8 | |
| SCHEMBL3104223 | 0.91 | PRSS12 (0.58) | PRSS12CHEK2MMP2MMP9MMP8 | |
| SCHEMBL11949000 | 0.89 | HPSE (0.53) | CHEK2MMP2MMP9MMP8MMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8232410-B2 | Benzimidazoles and pharmaceutical compositions thereof | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 2012-07-31 | — | — | US | disclosed |
| US-8232410-B2 | Benzimidazoles and pharmaceutical compositions thereof | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 2012-07-31 | — | — | US | disclosed |
| US-20100256203-A1 | BENZIMIDAZOLES AND PHARMACEUTICAL COMPOSITIONS THEREOF | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | 2010-10-07 | — | — | US | disclosed |
| US-20100256203-A1 | BENZIMIDAZOLES AND PHARMACEUTICAL COMPOSITIONS THEREOF | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | 2010-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256203-A1 | BENZIMIDAZOLES AND PHARMACEUTICAL COMPOSITIONS THEREOF | TBCD, TBC1D5, CFTR | PRSS12 2766/4885CHEK2 3766/4885MMP2 4155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.